Show simple item record

dc.contributor.author
Müller, Cristina
dc.contributor.author
Béhé, Martin
dc.contributor.author
Geistlich, Susanne
dc.contributor.author
van der Meulen, Nicholas P.
dc.contributor.author
Schibli, Roger
dc.date.accessioned
2021-01-25T12:02:29Z
dc.date.available
2021-01-07T19:24:24Z
dc.date.available
2021-01-25T12:02:29Z
dc.date.issued
2020-12
dc.identifier.issn
0009-4293
dc.identifier.other
10.2533/chimia.2020.939
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/460359
dc.identifier.doi
10.3929/ethz-b-000460359
dc.description.abstract
The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for successful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affinity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties that suit the properties of the targeting molecule and the clinical purpose. The Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute in Switzerland is privileged to be situated close to unique infrastructure for radionuclide production (high energy accelerators and a neutron source) and access to C/B-type laboratories including preclinical, nuclear imaging equipment and Swissmedic-certified laboratories for the preparation of drug samples for human use. These favorable circumstances allow production of non-standard radionuclides, exploring their biochemical and pharmacological features and effects for tumor therapy and diagnosis, while investigating and characterizing new targeting structures and optimizing these aspects for translational research on radiopharmaceuticals. In close collaboration with various clinical partners in Switzerland, the most promising candidates are translated to clinics for 'first-in-human' studies. This article gives an overview of the research activities at CRS in the field of TRT by the presentation of a few selected projects.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Swiss Chemical Society
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Folate, PSMA
en_US
dc.subject
Minigastrin
en_US
dc.subject
Radiopharmacy
en_US
dc.subject
Targeted radionuclide therapy
en_US
dc.subject
Terbium radio-nuclides
en_US
dc.subject
Theragnostics
en_US
dc.title
Targeted Radiotherapeutics from 'Bench-to-Bedside'
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2020-12-01
ethz.journal.title
Chimia
ethz.journal.volume
74
en_US
ethz.journal.issue
12
en_US
ethz.journal.abbreviated
Chimia
ethz.pages.start
939
en_US
ethz.pages.end
945
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.grant
Targeting Cancer Cells with Hybrid and Heterovalent Ligands at Controlled Distances
en_US
ethz.grant
Development of New Folate-Based RadioImaging Agents and RadioTherapeutics
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Bern
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.::02534 - Institut für Pharmazeutische Wiss. / Institute of Pharmaceutical Sciences::03688 - Schibli, Roger / Schibli, Roger
en_US
ethz.leitzahl.certified
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.::02534 - Institut für Pharmazeutische Wiss. / Institute of Pharmaceutical Sciences::03688 - Schibli, Roger / Schibli, Roger
en_US
ethz.grant.agreementno
160805
ethz.grant.agreementno
156803
ethz.grant.fundername
SNF
ethz.grant.fundername
SNF
ethz.grant.funderDoi
10.13039/501100001711
ethz.grant.funderDoi
10.13039/501100001711
ethz.grant.program
Sinergia
ethz.grant.program
Projektförderung in Biologie und Medizin (Abteilung III)
ethz.date.deposited
2021-01-07T19:24:38Z
ethz.source
FORM
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2021-01-25T12:02:41Z
ethz.rosetta.lastUpdated
2021-02-15T23:32:17Z
ethz.rosetta.exportRequired
true
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Targeted%20Radiotherapeutics%20from%20'Bench-to-Bedside'&rft.jtitle=Chimia&rft.date=2020-12&rft.volume=74&rft.issue=12&rft.spage=939&rft.epage=945&rft.issn=0009-4293&rft.au=M%C3%BCller,%20Cristina&B%C3%A9h%C3%A9,%20Martin&Geistlich,%20Susanne&van%20der%20Meulen,%20Nicholas%20P.&Schibli,%20Roger&rft.genre=article&rft_id=info:doi/10.2533/chimia.2020.939&
 Search print copy at ETH Library

Files in this item

Thumbnail

Publication type

Show simple item record